Enoxaparin (Clexane) Dosing: Prophylaxis vs Treatment
Prophylactic enoxaparin is typically dosed at 40 mg subcutaneously once daily, while therapeutic (treatment) dosing is 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg once daily. 1
Key Dosing Differences
Prophylactic Dosing
- Standard dose: 40 mg subcutaneously once daily 1
- Surgical patients: 40 mg given 2-4 hours preoperatively or 10-12 hours preoperatively, then 40 mg once daily thereafter 1
- Renal impairment (CrCl <30 mL/min): Reduce to 30 mg once daily 2
- Target anti-Xa level: 0.2-0.5 IU/mL (when monitoring is performed) 3
Therapeutic (Treatment) Dosing
- Standard regimens:
- 1 mg/kg every 12 hours, OR
- 1.5 mg/kg once daily 1
- Acute coronary syndromes: 1 mg/kg every 12 hours 4
- Renal impairment (CrCl <30 mL/min): Reduce to 1 mg/kg once every 24 hours 4, 2
- Target anti-Xa level: 0.6-1.0 IU/mL for twice-daily dosing; 1.0 IU/mL for once-daily dosing (measured 4 hours post-dose) 5
Clinical Context and Adjustments
The fundamental difference is approximately 2.5-3 fold higher total daily dose for treatment versus prophylaxis. For a 70 kg patient, prophylaxis provides 40 mg daily while treatment provides 140 mg daily (70 mg twice daily) or 105 mg daily (1.5 mg/kg once).
Special Populations Requiring Dose Modification
Renal insufficiency is the most critical factor requiring dose adjustment. With CrCl <30 mL/min, enoxaparin clearance is reduced by 44%, leading to a 2-3 fold increased bleeding risk if standard therapeutic doses are used 2, 5. This is why dose reduction is mandatory in severe renal impairment.
Obesity (BMI ≥40 kg/m²) may require adjusted prophylactic dosing to 40 mg twice daily rather than once daily, though therapeutic dosing should use actual body weight 6, 7. The evidence suggests standard weight-based therapeutic dosing is appropriate even in obesity 8.
Extreme low body weight (<50 kg) requires caution. For patients weighing approximately 22 kg, weight-based prophylactic dosing of 0.5 mg/kg has been used successfully 9.
Cancer-Associated VTE Considerations
For cancer patients requiring extended anticoagulation, therapeutic dosing may be reduced after the initial period—dalteparin (a similar LMWH) is reduced from 200 units/kg daily to 150 units/kg daily after 1 month, suggesting 75-80% of initial LMWH dose for extended therapy 6. While this specific reduction strategy is best established for dalteparin, the principle may apply to enoxaparin in extended cancer-associated VTE treatment.
Common Pitfalls
Do not use prophylactic doses for established VTE treatment—this is inadequate anticoagulation and increases thrombosis risk. One study showed 5 strokes occurred in atrial fibrillation patients receiving prophylactic rather than therapeutic doses 10.
Renal function must be assessed before dosing—failure to reduce doses in CrCl <30 mL/min substantially increases major bleeding risk (OR 3.88) 5.
Timing of anti-Xa monitoring matters—peak levels should be drawn 4 hours after administration for therapeutic dosing 5, not at trough. For prophylactic monitoring, levels are typically drawn at steady state after 3-4 doses.
In critically ill patients, standard therapeutic dosing achieves target anti-Xa levels in only 26-33% of patients 11, suggesting these populations may require dose adjustments guided by anti-Xa monitoring, though routine monitoring is not recommended for most patients 8.